Ken Griffin Arvinas, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Arvinas, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 26,700 shares of ARVN stock, worth $480,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

26,700

Previous 30,300 11.88%

Holding current value

$480,600

Previous $806,000 18.49%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$23.66 - $32.73 $1.61 Million - $2.23 Million	68,052 Added 2.58%	2,707,551 $66.7 Million
Q2 2024 Aug 14, 2024	BUY	$24.46 - $40.4 $8.78 Million - $14.5 Million	358,886 Added 15.74%	2,639,499 $70.3 Million
Q1 2024 May 15, 2024	SELL	$36.38 - $52.31 $5.8 Million - $8.34 Million	-159,368 Reduced 6.53%	2,280,613 $94.1 Million
Q4 2023 Feb 14, 2024	BUY	$14.19 - $42.33 $25.8 Million - $76.8 Million	1,815,403 Added 290.66%	2,439,981 $100 Million
Q3 2023 Nov 14, 2023	SELL	$19.64 - $28.21 $5.21 Million - $7.48 Million	-265,024 Reduced 29.79%	624,578 $12.3 Million
Q2 2023 Aug 14, 2023	SELL	$21.73 - $31.43 $4.28 Million - $6.2 Million	-197,137 Reduced 18.14%	889,602 $22.1 Million
Q1 2023 May 15, 2023	BUY	$26.15 - $37.26 $12.4 Million - $17.7 Million	475,777 Added 77.87%	1,086,739 $29.7 Million
Q4 2022 Feb 14, 2023	BUY	$32.47 - $57.24 $14.2 Million - $25 Million	436,992 Added 251.19%	610,962 $20.9 Million
Q3 2022 Nov 14, 2022	BUY	$41.87 - $57.99 $4.11 Million - $5.69 Million	98,083 Added 129.25%	173,970 $7.74 Million
Q2 2022 Aug 15, 2022	SELL	$36.01 - $74.24 $367,338 - $757,322	-10,201 Reduced 11.85%	75,887 $3.19 Million
Q1 2022 May 16, 2022	BUY	$60.27 - $81.57 $4.6 Million - $6.22 Million	76,292 Added 778.81%	86,088 $5.79 Million
Q4 2021 Feb 14, 2022	SELL	$65.85 - $96.21 $14.5 Million - $21.2 Million	-220,013 Reduced 95.74%	9,796 $804,000
Q3 2021 Nov 15, 2021	BUY	$73.2 - $107.87 $8.8 Million - $13 Million	120,258 Added 109.77%	229,809 $18.9 Million
Q2 2021 Aug 16, 2021	BUY	$60.45 - $84.26 $4.63 Million - $6.45 Million	76,525 Added 231.71%	109,551 $8.44 Million
Q1 2021 May 17, 2021	SELL	$58.19 - $91.37 $15.7 Million - $24.6 Million	-269,572 Reduced 89.09%	33,026 $2.18 Million
Q4 2020 Feb 16, 2021	SELL	$20.19 - $84.93 $1.43 Million - $6.03 Million	-70,999 Reduced 19.0%	302,598 $25.7 Million
Q3 2020 Nov 16, 2020	SELL	$22.99 - $36.34 $9.85 Million - $15.6 Million	-428,406 Reduced 53.42%	373,597 $8.82 Million
Q2 2020 Aug 14, 2020	BUY	$29.88 - $56.74 $21.7 Million - $41.3 Million	727,842 Added 981.43%	802,003 $26.9 Million
Q1 2020 May 15, 2020	BUY	$33.0 - $54.5 $814,935 - $1.35 Million	24,695 Added 49.92%	74,161 $2.99 Million
Q4 2019 Feb 14, 2020	BUY	$15.39 - $44.38 $761,281 - $2.2 Million	49,466 New	49,466 $2.03 Million
Q2 2019 Aug 14, 2019	SELL	$15.96 - $23.8 $809,251 - $1.21 Million	-50,705 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$13.55 - $23.79 $315,728 - $554,330	23,301 Added 85.03%	50,705 $0
Q3 2018 Nov 13, 2018	BUY	$16.05 - $16.87 $439,834 - $462,305	27,404 New	27,404 $0

Others Institutions Holding ARVN

# of Institutions

229

Shares Held

68.4M

Call Options Held

226K

Put Options Held

285K

View Full List

About ARVINAS, INC.

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $958M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

More about ARVN

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account